Galderma Expands Restylane Portfolio in Japan with OBT-Based Injectables
Event summary
- Galderma launched Restylane Defyne and Refyne, the first OBT-based hyaluronic acid injectables authorized in Japan.
- The products are designed for mid-to-deep dermis injections to correct moderate to severe facial wrinkles and folds.
- Restylane Defyne provides support for areas like the jawline, while Restylane Refyne offers a smooth, flexible gel for expressive areas.
- The approvals were based on pivotal phase III studies with 171 and 162 subjects respectively, showing clinically meaningful improvements for up to 12 months.
The big picture
Galderma's launch of OBT-based injectables in Japan aligns the market with global standards, reinforcing its position as a leader in aesthetic dermatology. This expansion supports the company's JPAC growth strategy and addresses significant trends such as menopause-related skin health and medication-driven weight loss. With over 77 million treatments administered worldwide, Restylane remains highly relevant in addressing diverse aesthetic needs.
What we're watching
- Market Penetration
- How the introduction of OBT technology will affect Galderma's market share in Japan's dynamic aesthetics sector.
- Clinical Adoption
- Whether physicians will widely adopt Restylane Defyne and Refyne, given their tailored treatment capabilities.
- Regional Growth
- The pace at which Galderma can expand its Restylane portfolio in other high-growth Asia-Pacific markets.
Related topics